Home › Funds › Ikarian Capital, LLC › EPRX
Ikarian Capital, LLC position in EPRX
EUPRAXIA PHARMACEUTICALS INC · Health Care
Ikarian Capital, LLC reported holding 809,741 shares of EPRX (EUPRAXIA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$7.4M, representing 1.08% of its reported portfolio and ranking #22 among its reported holdings. Ikarian Capital, LLC has disclosed EPRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's EPRX position evolved
Ikarian Capital, LLC first disclosed a stake in EPRX in Q4 2025 at 610,000 shares (US$4.6M). The position peaked in Q1 2026 at 1,214,741 shares, worth US$8.8M. Across 4 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 809,741 shares valued at US$7.4M. Notable position changes include a 99% increase in Q1 2026 (shares fell 9% over the following quarter), a 33% trim in Q2 2026 (shares rose 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 610.00K | $4.61M | New |
| Q1 2026 | 1.21M | $8.79M | Add |
| Q2 2026 | 809.74K | $5.35M | Reduce |
| Q3 2026 | 809.74K | $7.37M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EPRX and 13F data
EPRX (EUPRAXIA PHARMACEUTICALS INC) is a Health Care company. 72 other funds we track also report a position in EPRX — the largest reported positions include Bellevue Group AG (US$23.6M), Affinity Asset Advisors, LLC (US$15.6M), Vivo Capital, LLC (US$12.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EPRX
- Bellevue Group AG 2.60M sh · $23.62M · Q3 2026
- Affinity Asset Advisors, LLC 1.72M sh · $15.62M · Q3 2026
- Vivo Capital, LLC 1.35M sh · $12.29M · Q3 2026
- GREAT POINT PARTNERS LLC 1.20M sh · $10.92M · Q3 2026
- Caligan Partners LP 1.16M sh · $10.58M · Q3 2026
- PFM Health Sciences, LP 1.13M sh · $10.26M · Q3 2026
- Seven Fleet Capital Management LP 572.27K sh · $5.21M · Q3 2026
- Redmile Group, LLC 519.88K sh · $4.73M · Q3 2026
- DAFNA Capital Management LLC 404.57K sh · $3.68M · Q3 2026
- Velan Capital Investment Management LP 352.00K sh · $3.20M · Q3 2026
- Aisling Capital Management LP 325.00K sh · $2.96M · Q3 2026
- DV EQUITIES, LLC 276.00K sh · $2.51M · Q3 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held EPRX?
Ikarian Capital, LLC has disclosed EPRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Ikarian Capital, LLC's current position in EPRX?
As of Q3 2026, Ikarian Capital, LLC holds 809.74K shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), valued at $7.37M, representing 1.08% of its reported portfolio and ranking #22.
Has Ikarian Capital, LLC been buying or selling EPRX?
In the latest 13F filing (Q3 2026), Ikarian Capital, LLC held unchanged its position in EPRX. The position peaked in Q1 2026 at 1.21M shares.
Which other funds hold EPRX?
Other major institutional holders of EPRX include Bellevue Group AG, Affinity Asset Advisors, LLC, Vivo Capital, LLC, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.